中国肝脏病杂志（电子版）
中國肝髒病雜誌（電子版）
중국간장병잡지（전자판）
Chinese Journal of Liver Diseases (Electronic Version)
2015年
3期
100-102
,共3页
王玮%田勇%李玉芬%路运健
王瑋%田勇%李玉芬%路運健
왕위%전용%리옥분%로운건
原发性胆汁性肝硬化%安络化纤丸%熊去氧胆酸胶囊
原髮性膽汁性肝硬化%安絡化纖汍%熊去氧膽痠膠囊
원발성담즙성간경화%안락화섬환%웅거양담산효낭
Primary biliary cirrhosis%Anluohuaxian pills%Ursodeoxycholic acid capsules
目的：观察安络化纤丸联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化患者的疗效。方法随机将64例原发性胆汁性肝硬化患者分为治疗组32例和对照组32例。对照组32例给予甘草酸二胺肠溶胶囊、熊去氧胆酸胶囊（UDCA）治疗，治疗组在对照组基础上加用安络化纤丸，疗程均为三个月。观察治疗前后患者临床症状、体征的变化以及肝功能、肝纤维化、肝脾影像学变化。结果两组患者在治疗过程中均未出现明显不良反应。两组疗效相比，治疗组有效率90.6%，明显高于对照组68.8%（P =0.024)；治疗后血清ALT、AST、ALP、GGT水平相比，治疗组较对照组显著减低（aP =0.082，*P =0.0008，#P =0.037）；治疗后肝脾影像学变化，治疗组较对照组有显著改善（aP =0.021)；结论安络化纤丸与熊去氧胆酸胶囊联合治疗原发性胆汁性肝硬化临床效果明显、不良反应少，可以改善患者临床不适、体征、肝功能、肝纤维化及临床肝脏影像学指标。
目的：觀察安絡化纖汍聯閤熊去氧膽痠膠囊治療原髮性膽汁性肝硬化患者的療效。方法隨機將64例原髮性膽汁性肝硬化患者分為治療組32例和對照組32例。對照組32例給予甘草痠二胺腸溶膠囊、熊去氧膽痠膠囊（UDCA）治療，治療組在對照組基礎上加用安絡化纖汍，療程均為三箇月。觀察治療前後患者臨床癥狀、體徵的變化以及肝功能、肝纖維化、肝脾影像學變化。結果兩組患者在治療過程中均未齣現明顯不良反應。兩組療效相比，治療組有效率90.6%，明顯高于對照組68.8%（P =0.024)；治療後血清ALT、AST、ALP、GGT水平相比，治療組較對照組顯著減低（aP =0.082，*P =0.0008，#P =0.037）；治療後肝脾影像學變化，治療組較對照組有顯著改善（aP =0.021)；結論安絡化纖汍與熊去氧膽痠膠囊聯閤治療原髮性膽汁性肝硬化臨床效果明顯、不良反應少，可以改善患者臨床不適、體徵、肝功能、肝纖維化及臨床肝髒影像學指標。
목적：관찰안락화섬환연합웅거양담산효낭치료원발성담즙성간경화환자적료효。방법수궤장64례원발성담즙성간경화환자분위치료조32례화대조조32례。대조조32례급여감초산이알장용효낭、웅거양담산효낭（UDCA）치료，치료조재대조조기출상가용안락화섬환，료정균위삼개월。관찰치료전후환자림상증상、체정적변화이급간공능、간섬유화、간비영상학변화。결과량조환자재치료과정중균미출현명현불량반응。량조료효상비，치료조유효솔90.6%，명현고우대조조68.8%（P =0.024)；치료후혈청ALT、AST、ALP、GGT수평상비，치료조교대조조현저감저（aP =0.082，*P =0.0008，#P =0.037）；치료후간비영상학변화，치료조교대조조유현저개선（aP =0.021)；결론안락화섬환여웅거양담산효낭연합치료원발성담즙성간경화림상효과명현、불량반응소，가이개선환자림상불괄、체정、간공능、간섬유화급림상간장영상학지표。
Objective To observe the treatment effect of Anluohuaxian pills combined ursodeoxycholic acid capsules on primary biliary cirrhosis patients. Methods Total of 64 patients with primary biliary cirrhosis were randomly divided into treatment group (32 cases) and control group (32 cases). The control group were given diammonium glycyrrhizinate enteric-coated capsules and ursodeoxycholic acid capsules (UDCA), and the treatment group were treated with Anluohuaxian pills on the basis of the control group. After a treatment course of three months, the changes of clinical symptoms, physical signs, liver function, liver fibrosis, and liver and spleen imaging were observed and compared with before treatment. Results No obvious adverse reaction occurred in the two groups during the treatment. The efficiency of the treatment group (90.6%) was significantly higher than the control group (68.8%) (P = 0.024). The level of serum ALT, AST, ALP, GGT of the treatment group decreased significantly (aP = 0.082, *P = 0.0008,#P = 0.037) compared with the control group. After treatment, the liver and spleen imaging changes of the treatment group significantly improved in liver photoelectric intensive compared with the control group (aP < 0.021). Conclusions Anluohuaxian pills combined with ursodeoxycholic acid capsules have obvious curative treatment effects and less side effects on primary biliary cirrhosis and can improve fibrosis and clinical indexes of liver imaging.
